RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish a clinics-centered integrated system that spans the pharmaceutical industry, academia, and research fields, with a focus on antibody-drug conjugate (ADC) development.
RemeGen’s ADC Achievements and Pipeline
RemeGen’s disitamab vedotin marked a significant milestone as the first home-grown ADC to emerge from China, obtaining conditional market approval in June 2021 for use as a third-line treatment for HER2-positive gastric cancer (GC). This approval underscores RemeGen’s commitment to advancing targeted cancer therapies.
Expanding ADC Pipeline and Research Collaboration
In addition to disitamab vedotin, RemeGen’s pipeline includes several other ADC candidates under development, such as RC88 targeted mesothelin, RC108 targeted c-Met, and RC118 targeted Claudin 18.2. The company is also working on RC168, RC178, and RC188, indicating a robust pipeline of potential new treatments for various types of cancer. This collaboration with Shandong Cancer Hospital is expected to further enhance RemeGen’s research and development capabilities in the ADC space.-Fineline Info & Tech
